Cue Biopharma, Inc.
CUE
$0.56
-$0.01-1.75%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.10M | 8.29M | 7.99M | 9.29M | 9.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.10M | 8.29M | 7.99M | 9.29M | 9.53M |
| Cost of Revenue | 25.77M | 26.08M | 27.70M | 29.35M | 33.06M |
| Gross Profit | -18.67M | -17.79M | -19.71M | -20.07M | -23.52M |
| SG&A Expenses | 15.71M | 13.94M | 13.77M | 13.79M | 14.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.21M | 47.76M | 49.21M | 50.88M | 55.17M |
| Operating Income | -38.11M | -39.48M | -41.22M | -41.59M | -45.64M |
| Income Before Tax | -37.68M | -38.90M | -40.58M | -40.67M | -44.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.68 | -38.90 | -40.58 | -40.67 | -44.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.68M | -38.90M | -40.58M | -40.67M | -44.61M |
| EBIT | -38.11M | -39.48M | -41.22M | -41.59M | -45.64M |
| EBITDA | -37.73M | -39.08M | -40.82M | -41.20M | -45.23M |
| EPS Basic | -0.46 | -0.55 | -0.66 | -0.75 | -0.91 |
| Normalized Basic EPS | -0.28 | -0.35 | -0.42 | -0.47 | -0.57 |
| EPS Diluted | -0.46 | -0.55 | -0.66 | -0.75 | -0.91 |
| Normalized Diluted EPS | -0.28 | -0.35 | -0.42 | -0.47 | -0.57 |
| Average Basic Shares Outstanding | 344.82M | 295.18M | 249.90M | 225.11M | 198.07M |
| Average Diluted Shares Outstanding | 344.82M | 295.18M | 249.90M | 225.11M | 198.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |